{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:20:41Z","timestamp":1791948041420,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.resinv.2015.06.001","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T21:15:25Z","timestamp":1439846125000},"page":"232-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"53","author":[{"given":"Takashi","family":"Ogura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingo","family":"Chida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kakutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritaka","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nukiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2015.06.001_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2015.06.001_bib4","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2015.06.001_bib6","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2015.06.001_bib7","first-page":"9","article-title":"Non-steroid agents for idiopathic pulmonary fibrosis","author":"Spagnolo","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.resinv.2015.06.001_bib8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.159.4.9805017","article-title":"Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of prospective, open-label phase II study","volume":"159","author":"Raghu","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2169\/internalmedicine.41.1118","article-title":"Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis","volume":"41","author":"Nagai","year":"2002","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib12","series-title":"Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonias","article-title":"Japanese Respiratory Society\u05f3s Committee formulating diagnosis and treatment guideline for diffuse lung diseases","year":"2011"},{"key":"10.1016\/j.resinv.2015.06.001_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1465-9921-12-143","article-title":"Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment","volume":"12","author":"Azuma","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2015.06.001_bib14","first-page":"577","article-title":"The clinical diagnosis of pulmonary emphysema; an experimental study","volume":"45","author":"Fletcher","year":"1952","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1081\/BIP-100104194","article-title":"Accounting for dropout bias using mixed-effects models","volume":"11","author":"Mallinckrodt","year":"2001","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.resinv.2015.06.001_bib16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.resinv.2015.06.001_bib17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2015.06.001_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-12-93","article-title":"The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial","volume":"12","author":"Taniguchi","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2015.06.001_bib19","series-title":"Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"Zimmerman","year":"1999"},{"key":"10.1016\/j.resinv.2015.06.001_bib20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/resp.12297","article-title":"Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"19","author":"Valeyre","year":"2014","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2015.06.001_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.resinv.2013.09.002","article-title":"Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis","volume":"52","author":"Arai","year":"2014","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2015.06.001_bib22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.rmed.2013.06.011","article-title":"Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice","volume":"107","author":"Okuda","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib23","first-page":"518","article-title":"Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis","volume":"138","author":"Bonella","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.resinv.2015.06.001_bib24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","article-title":"Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis","volume":"168","author":"Collard","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.127.1.171","article-title":"Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis","volume":"127","author":"King","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2015.06.001_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1164\/rccm.201406-1106LE","article-title":"Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis","volume":"191","author":"Loeh","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2015.06.001_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.pupt.2013.06.009","article-title":"Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs","volume":"5","author":"Okazaki","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.resinv.2015.06.001_bib28","doi-asserted-by":"crossref","unstructured":"Chiba H, Natsuizaka M, Shiratori M, et al. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido. The annual report by study group of ministry of health and welfare for diffuse lung diseases; 2012. p. 125\u201334.","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A4587"},{"key":"10.1016\/j.resinv.2015.06.001_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534515000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534515000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T13:19:21Z","timestamp":1567084761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534515000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S2212534515000787"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2015.06.001","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2015.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Respiratory Society. Published by Elsevier Japan KK All rights reserved.","name":"copyright","label":"Copyright"}]}}